Zoetis Q4 2025 Beats Estimates, Eyes Strong FY 2026 Growth Amid Biologics PushZoetis beats Q4 2025 earnings, tops revenue and EPS forecasts, and ramps up biologics and companion‑animal vaccines, boosting FY‑2026 outlook.Zoetis Inc Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated Dr. Michael Chen 14/02/2026, 21:50 4 minutes to read